Bernd Hentsch, PhD

Chief Development Officer

Bernd Hentsch serves as Chief Development Officer at Inthera and has been with the company since 2015. Bernd is looking back on a professional track record of more than two decades, consisting of research in international academic institutes (i.e., the Walter & Eliza Hall Institute, Melbourne, and the German Cancer Research Center, Heidelberg) and of drug development in various pharmaceutical and biotech companies (Merck KGaA, TopoTarget A/S, 4SC AG, Inthera). With a PhD in molecular biology in the area of oncology/immunology from the University of Würzburg, Bernd has focussed his work on the development of innovative and new treatment options for the therapy of cancer patients.